The Organisation of Pharmaceutical Producers of India (OPPI) on monday reassured availability of adequate supplies of medicines amid the co...

OPPI, which represents research-driven pharma companies in India, has continued its advocacy for an environment that allows innovation in m...

This would lead to increased levels of transparency and accountability across the healthcare industry and remove ambiguity.

OPPI feels that while India provides an attractive low cost destination to outsource R&D activities.

The OPPI has pitched in for the rationalisation of central excise duty rate of inputs (Active Pharmaceutical Ingredients or API) from 12% t...

OPPI justified its argument by stating that it is imperative that critical life saving drugs be made available to the patients at reduced p...

The single year data pertaining to the year of international transaction is most often not available at the time of carrying out the benchm...

OPPI indicated that import of Pharma Grade Un-denatured Ethanol used in manufacture of anti-cancer formulations should enjoy exemption/redu...

The OPPI has asked for the exemption from levy of central excise duty for physician samples as in line with exemption from levy of VAT in B...

OPPI explained that Safe Harbor has been defined to mean 'circumstances' in which the revenue authorities shall accept the transfer pricing...

OPPI says that the Indian transfer pricing regulations advocate the use of arithmetic mean for computation of Arm’s Length Price.

OPPI suggests that instead, the regulations should prescribe for the use of inter-quartile range, which would be a better representative of...

OPPI, however, said that current guidelines do not provide for roll back of APAs i.e., its applicability to past open litigation.

OPPI has proposed that Budget 2013 should amend Specified Domestic Transactions. The proposed amendment seeks to cover a situation wherein ...

According to OPPI, basic customs duty(BCD) for health supplements should be slashed to 10% and additional customs duty(ACD)/central excise ...

OPPI has asked for a cut in the additional customs duty(ACD) to 2% from 6% on import of vaccines, specified medicaments and health suppleme...

Sustaining pharma industry growth is a challenge due to uncertainties and lack of ecosystem that fosters innovation, OPPI president said.